Og at opsjoner har en innløsningsfrist 
Har ikke sjekket fristene i BergenBio da.
1 Like
Arctic sier BUY hever TP til NOK86 fra 65 - Unique COVID-19 possibility
“We raise our target price to NOK 86 - Reiteration of BUY recommendation with increased target price due to the unique fast-track Covid-19 indication. An important trigger is the read-out of the phase 2 study in approx. 6 weeks. If the study fails the Covid-19 indication will be removed, and if the study succeeds the TP will increase significantly.”
9 Likes
BerGenBio ASA: Share capital increase
1 Like
Ikke sett på maken til coverage
32 Likes
Firms across the healthcare sector are working day and night to develop the first approved treatment for patients with Covid-19 — and, in the UK, BerGenBio looks to be a leading name in this particular race. 
8 Likes
Så lenge det er en overhengende rep.emi og arbitrasjemulighet så vil vel ikke kursen stige så mye uten news. Hvis kusen stiger til 50 så kan jeg selge for 50 og kjøpe for 37.5.
1 Like
Jeg synes du overdriver betydningen av arbitrasjemuligheten. Det kommer maks 1,5 mill nye aksjer i reparasjonsemisjonen. Da blir det bare 3-4% ekstra aksjer på hver aksjonær som ikke var med på den rettede emisjonen. Det burde ikke holde noen tilbake om de liker aksjen.
6 Likes
Det du sier er helt korrekt, men jeg tror likevel at det er den effekten vi nå ser.
Oslo børs er en liten andedam som har angst for emisjoner og betrakter aksjonærlister som veiledning for en slags monetær astroligogi.
Klart, dersom det nå kommer veldig positive news så vil aksjen leve sitt eget liv.
3 Likes
BERGENBIO ASA: Invitation to first quarter 2020 results webcast presentation
7 Likes
@Savepig og dere andre Biotech`ere
Ref. COVID-19 ACCORD analysen til Arctic.
Hvor mye skal man legge i dette med %LOA i tilfeller som dette?
Kan ikke si jeg ble beroliget av beregnet sannsynlighet for suksess.
Generell LOA (infeksjoner) :
LoA from Ph2: 27,5%
Bemcentinib ACCORD LOA:
Beste scenario - LOA: 25 %
- sikkerhet kjent fra kreft studier.
Medium scenario - LOA: 12%
- Ingen effekt data på menneske, lavere sannsynlighet er forventet.
Dårligste scenario - LOA 8%
- Ingen effekt data på menneske
- Konkurranse situasjon, 571 andre Covid-19 medisiner i utvikling/studie.
Snittet utgjør LOA 14%.
Hvor kommer så de 80% til CEO inn her?
Med 80% er man oppe på Ph3 -> Sub - Sub–>Approval ref. analysen.
3 Likes
Som vel er i tråd med deres investeringsmandat, de skal jo være en tidligfase investor.
1 Like
Har ingenting å si for morgendagen. De informerer bare hvorfor % andelen i antall aksjer er gått ned. De har ikke solgt, men en naturlig følge av emisjonen.
1 Like
Gleder meg til å se dollar gliset til 80%-Godfrey 
En smørblid og travel CEO
5 Likes
# CEO LETTER COVID-19 CLINICAL TRIAL
These are unprecedented and challenging times. My priority has been the safety and health of our employees and their families, and to continue the Company’s clinical trials as far as is feasibly possible.
At the same time, we have been working hard to see how we might help in the fight against COVID-19 more directly. On 28 April we announced our participation in a new UK national multi-centre randomised Phase 2 clinical trial initiative called ACCORD ( AC celerating C OVID-19 R esearch & D evelopment platform). BerGenBio’s bemcentinib was selected as the first candidate to be tested for its efficacy and safety in patients hospitalised with COVID-19.
Whilst our clinical focus for bemcentinib , a highly selective and potent inhibitor of AXL kinase, has been on the treatment of cancer, we have been aware of bemcentinib’s anti-viral potential for some time, as demonstrated in preclinical models against viruses such as Ebola and Zika, with recent data expanding this to SARS-CoV-2. Bemcentinib selectively inhibits AXL kinase activity, blocking viral entry and enhancing the anti-viral type I interferon response, a key cellular defence mechanism against viral infection.
We are aware of the privilege and importance of having our drug selected for this national study and will be working closely with the Government Scientific Office, the National Institute for Health Research and designated CRO IQVIA to produce timely and high-quality results. If positive results are seen, bemcentinib will advance rapidly to Phase 3 testing and prepare for commercialisation to treat COVID-19 patients.
I’m particularly grateful and impressed by the vital pre-clinical research carried out by Professor Wendy Maury and her team at the University of Iowa, which discovered that the essential role of AXL is hi-jacked by viruses such as EBOLA and SARS-CoV-2 to enhance their infection rate and substantially improve their survival in host cells, and furthermore demonstrated the potential of bemcentinib as a treatment for viruses such as COVID-19. I also thank, and recognise the incredible effort made by, the BerGenBio team, alongside Tom Wilkinson’s team at the University of Southampton and IQVIA, to enable this important trial to get started so rapidly.
As for any company in the healthcare industry, we are seeking to improve the lives and treatment options for patients across the globe. This study will be important not only for COVID-19 patients, but should also serve to further validate bemcentinib as a promising treatment candidate for other aggressive diseases.
We look forward to keeping you all updated as we progress with the study, with the hope that bemcentinib can contribute to the global efforts to find an effective treatment for COVID-19.
Richard Godfrey
Chief Executive Officer of BerGenBio ASA
12 Likes
Når ble denne skrevet?
1 Like
Sjekk ut nettsiden til BergenBio, der finner du svar …
Der er den også lagt ut på Norsk.
1 Like
- april
Står i brevet…
1 Like